Key result
Dexmedetomidine significantly reduced heart rate (SMD -1.71; 95% CI -2.29 to -1.13) and the frequency of Junctional Ectopic Tachycardia in pediatric patients undergoing cardiac surgery.
Why the study?
This study was conducted to investigate the effectiveness and adverse events of dexmedetomidine in maintaining hemodynamic stability in pediatric cardiac surgery.
Does dexmedetomidine improve hemodynamic stability in pediatric patients undergoing cardiac surgery?
Meta-Analysis
Does dexmedetomidine improve hemodynamic stability in pediatric patients undergoing cardiac surgery?
Standardized Mean Difference: -1.71 (95% CI -2.29–-1.13)
Dexmedetomidine is effective for maintaining hemodynamic stability and reducing heart rate and junctional ectopic tachycardia in pediatric patients undergoing cardiac surgery without significantly increasing adverse events.
Supports dexmedetomidine for hemodynamic stability in pediatric cardiac surgery; strengthens Level 1 evidence for perioperative use.
No takes yet. Share an insight, caveat, or question.
Chuikai Chen (2021) conducted a meta-analysis in Pediatric cardiac surgery. Dexmedetomidine vs. Placebo was evaluated on Heart rate (HR) (SMD -1.71, 95% CI -2.29, -1.13). Dexmedetomidine significantly reduced heart rate (SMD -1.71; 95% CI -2.29 to -1.13) and the frequency of Junctional Ectopic Tachycardia in pediatric patients undergoing cardiac surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: